Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05661604 · ClinicalTrials.gov registry record
A Study to Investigate Acute Respiratory Virus Infections in Participants at High Risk for Severe Illness
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 140
- Enrollment target
NCT05661604: Completed study, sponsored by Janssen Research & Development.
NCT05661604 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 140 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05661604 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 140 participants
- Enrollment target
Study Summary
The purpose of the study is to describe the rate of occurrence of clinical diagnosis of acute respiratory infection (an infection that affects normal breathing) and different types of respiratory pathogens (harmful organisms) of new respiratory infections in a population at high risk for severe illness.
Primary Outcome
Number of participants with clinically confirmed ARI will be reported.
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2023-01-19 |
| Est. Completion | 2024-03-31 |
What the finished NCT05661604 record still lists
NCT05661604 is an observational study that tracks outcomes without assigning an intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT05661604 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05661604 about?
NCT05661604 is a clinical study titled "A Study to Investigate Acute Respiratory Virus Infections in Participants at High Risk for Severe Illness". The purpose of the study is to describe the rate of occurrence of clinical diagnosis of acute respiratory infection (an infection that affects normal breathing) and different types of respiratory pathogens (harmful organisms) of new respiratory infections in a population at high risk for severe illn...
What is the current status of trial NCT05661604?
This trial is currently completed. The enrollment target is 140 participants. The study started on 2023-01-19. Estimated completion is 2024-03-31.
What interventions are being tested in trial NCT05661604?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT05661604?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI